TaiRx, Inc. (TPEX:6580)
Taiwan · Delayed Price · Currency is TWD 21.50
+0.05 (0.23%)
Jan 21, 2026, 1:59 PM CST
TaiRx Revenue
TaiRx had revenue of 7.50M TWD in the half year ending June 30, 2025, with 27,692.59% growth. This brings the company's revenue in the last twelve months to 15.46M, up 190.62% year-over-year. In the year 2024, TaiRx had annual revenue of 8.22M with 61.79% growth.
Revenue (ttm)
15.46M
Revenue Growth
+190.62%
P/S Ratio
153.92
Revenue / Employee
n/a
Employees
29
Market Cap
2.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.22M | 3.14M | 61.79% |
| Dec 31, 2023 | 5.08M | -1.84M | -26.59% |
| Dec 31, 2022 | 6.92M | 1.78M | 34.66% |
| Dec 31, 2021 | 5.14M | 1.78M | 53.05% |
| Dec 31, 2020 | 3.36M | 203.00K | 6.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |
| Caliway Biopharmaceuticals | 34.99M |